Update on rufinamide in childhood epilepsy

Update on rufinamide in childhood epilepsy

Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1) methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticonvulsant drugs. It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in the United States in 2004, and released for use in Europe in 2007. In January 2009, rufinamide was a...

Update on Feline Epilepsy

Paradigm Shifts in Feline Epilepsies The classification of epilepsy is a constantly evolving process, and thus is subject to continuous scrutiny and controversy. There are four main categories of epilepsy including genetic (primary/idiopathic), structural/metabolic (symptomatic), unknown (cryptogenic), and presumptive unknown. Although some breeds of cats have been reported as predisposed to de...

The Efficacy and Tolerability of Rufinamide in Intractable Pediatric Epilepsy

BACKGROUND AND PURPOSE Rufinamide (RUF) is a novel antiepileptic drug (AED) and its efficacy has been proven in Lennox-Gastaut syndrome (LGS). However, there is a lack of data regarding the efficacy in pediatric intractable epilepsies other than LGS. The purpose of the study was to explore the efficacy and tolerability of RUF in pediatric patients with intractable epilepsies as well as LGS. M...

O21: Update and Future Directions in Poststroke Epilepsy

لطفاً به چکیده انگلیسی مراجعه شود.

Update on vasculitis in childhood